Safety of Breastfeeding During Favipiravir Therapy: A Case Study.

IF 2.1 4区 医学 Q2 NURSING Journal of Human Lactation Pub Date : 2024-11-26 DOI:10.1177/08903344241296034
Yuka Sano Wada, Jumpei Saito, Wakako Yamamoto, Yuka Maegawa, Taro Kamiya, Katsumi Mizuno
{"title":"Safety of Breastfeeding During Favipiravir Therapy: A Case Study.","authors":"Yuka Sano Wada, Jumpei Saito, Wakako Yamamoto, Yuka Maegawa, Taro Kamiya, Katsumi Mizuno","doi":"10.1177/08903344241296034","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Favipiravir is a known anti-influenza agent that has been used globally, especially during the coronavirus disease 2019 (COVID-19) pandemic. This drug has been important for treating influenza and other emerging infectious diseases, although it was ultimately proven to be ineffective for COVID-19. Currently, no studies have reported the human-milk transfer of favipiravir at doses of 1,600-3,600 mg/day in the treatment of diseases, including COVID-19.</p><p><strong>Main issue: </strong>A 38-year-old mother gave birth at 38 gestational weeks because of severe respiratory distress caused by COVID-19. Considering her illness and the inadequate information available on the safety of favipiravir in breastfeeding, she chose formula feeding for her infant. However, she still provided human milk and blood samples for the analysis of drug concentrations.</p><p><strong>Management: </strong>Five concentrations of favipiravir in the mother's milk and four in maternal blood were measured (3.0-80.9 and 3.5-78.4 μg/ml, respectively). Metabolites of favipiravir were not measured. The relative infant dose was 15.2%. The favipiravir concentration in human milk was as high as 80.9 μg/ml at 1.3 hours after the medication was given, when maternal blood levels are considered to be at their highest; however, favipiravir concentration was low in human milk immediately before medication administration (5.9-9.7 μg/ml).</p><p><strong>Conclusion: </strong>Breastfeeding is not contraindicated in mothers undergoing favipiravir therapy and would be safer immediately before medication. Avoiding feeding at the peak time (1.3 hours after medication) minimizes infant exposure.</p>","PeriodicalId":15948,"journal":{"name":"Journal of Human Lactation","volume":" ","pages":"8903344241296034"},"PeriodicalIF":2.1000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Human Lactation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/08903344241296034","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NURSING","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Favipiravir is a known anti-influenza agent that has been used globally, especially during the coronavirus disease 2019 (COVID-19) pandemic. This drug has been important for treating influenza and other emerging infectious diseases, although it was ultimately proven to be ineffective for COVID-19. Currently, no studies have reported the human-milk transfer of favipiravir at doses of 1,600-3,600 mg/day in the treatment of diseases, including COVID-19.

Main issue: A 38-year-old mother gave birth at 38 gestational weeks because of severe respiratory distress caused by COVID-19. Considering her illness and the inadequate information available on the safety of favipiravir in breastfeeding, she chose formula feeding for her infant. However, she still provided human milk and blood samples for the analysis of drug concentrations.

Management: Five concentrations of favipiravir in the mother's milk and four in maternal blood were measured (3.0-80.9 and 3.5-78.4 μg/ml, respectively). Metabolites of favipiravir were not measured. The relative infant dose was 15.2%. The favipiravir concentration in human milk was as high as 80.9 μg/ml at 1.3 hours after the medication was given, when maternal blood levels are considered to be at their highest; however, favipiravir concentration was low in human milk immediately before medication administration (5.9-9.7 μg/ml).

Conclusion: Breastfeeding is not contraindicated in mothers undergoing favipiravir therapy and would be safer immediately before medication. Avoiding feeding at the peak time (1.3 hours after medication) minimizes infant exposure.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
法维拉韦治疗期间母乳喂养的安全性:个案研究。
简介法维拉韦是一种已知的抗流感药物,已在全球范围内使用,特别是在冠状病毒病 2019(COVID-19)大流行期间。这种药物对于治疗流感和其他新出现的传染病非常重要,尽管它最终被证明对 COVID-19 无效。目前,还没有研究报告称,在治疗包括COVID-19在内的疾病时,剂量为1,600-3,600毫克/天的法非拉韦会发生人乳转移:一位 38 岁的产妇因 COVID-19 引起的严重呼吸困难而在妊娠 38 周时分娩。考虑到她的病情以及有关母乳喂养中法非拉韦安全性的信息不足,她为婴儿选择了配方奶喂养。不过,她仍然提供了母乳和血液样本用于药物浓度分析:管理:在母亲的乳汁中测得了五种浓度的法非拉韦,在母亲的血液中测得了四种浓度的法非拉韦(分别为 3.0-80.9 和 3.5-78.4 μg/ml)。未检测到法非拉韦的代谢物。相对婴儿剂量为 15.2%。服药1.3小时后,母乳中的法非拉韦浓度高达80.9微克/毫升,此时母体血液中的法非拉韦浓度被认为是最高的;然而,服药前母乳中的法非拉韦浓度较低(5.9-9.7微克/毫升):结论:接受法非拉韦治疗的母亲并不禁忌母乳喂养,而且在用药前母乳喂养更为安全。避免在用药高峰期(用药后 1.3 小时)喂奶可最大限度地减少婴儿接触药物的机会。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Human Lactation
Journal of Human Lactation 医学-妇产科学
CiteScore
5.00
自引率
11.50%
发文量
100
审稿时长
6-12 weeks
期刊介绍: Committed to the promotion of diversity and equity in all our policies and practices, our aims are: To provide our readers and the international communities of clinicians, educators and scholars working in the field of lactation with current and quality-based evidence, from a broad array of disciplines, including the medical sciences, basic sciences, social sciences and the humanities. To provide student and novice researchers, as well as, researchers whose native language is not English, with expert editorial guidance while preparing their work for publication in JHL. In each issue, the Journal of Human Lactation publishes original research, original theoretical and conceptual articles, discussions of policy and practice issues, and the following special features: Advocacy: A column that discusses a ‘hot’ topic in lactation advocacy About Research: A column focused on an in-depth discussion of a different research topic each issue Lactation Newsmakers: An interview with a widely-recognized outstanding expert in the field from around the globe Research Commentary: A brief discussion of the issues raised in a specific research article published in the current issue Book review(s): Reviews written by content experts about relevant new publications International News Briefs: From major international lactation organizations.
期刊最新文献
Immunological Factors and Macronutrient Content in Human Milk From Women With Subclinical Mastitis. Considerations When Measuring Exclusive Breastfeeding. Bridging the Gap Between Lactation Care and Research in Human Lactation. Utilizing Lactation Acuity to Improve Lactation Services in a U.S. Hospital. Breastfeeding Intentions, Attitudes, and Knowledge Among Medical Students in Croatia.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1